We hope this email finds you safe and well. Pfizer has been closely monitoring developments with the COVID-19 pandemic and still feel that the outbreak is too unpredictable to host a face-to-face meeting this year. With this in mind, we are excited to announce that this year’s ELEVATE will now take place in a virtual setting on the 13th and 14th November 2020.
We invite you to ‘save the date’ ready to join your colleagues and a global faculty of experts in mBC management, real-word-evidence and patient communications for a collaborative virtual event.
Four different 90-minute webinars will be hosted across the two dates, allowing opportunity for experience exchange, Q&A, case study discussion and expert panel conversations. On-demand content will also be made available after the meeting ends.
The introduction of CDK4/6 inhibitors has transformed the treatment landscape for patients with HR+/HER2– mBC, presenting novel scenarios and expectations towards managing breast cancer care in the clinic.1 As such, ELEVATE will delve into the practical, real-world value of advances shaping the optimal treatment of patients with HR+/HER2– mBC through a dynamic and engaging agenda.